Clinical practice guidelines for paediatric X-linked hypophosphataemia in the era of burosumab

Abstract

X-linked hypophosphataemia (XLH), the most common inherited form of rickets, is caused by a PHEX gene mutation that leads to excessive serum levels of fibroblast growth factor 23 (FGF23). This leads to clinical manifestations such as rickets, osteomalacia, pain, lower limb deformity and overall diminished quality of life. The overarching aims in the management of children with XLH are to improve quality of life by reducing overall burden of disease, optimise an individual's participation in daily activities and promote normal physical and psychological development. Burosumab, a monoclonal antibody targeting FGF23, has been shown to improve biochemistry, pain, function and radiological features of rickets in children with XLH and has transformed management of XLH around the world. Burosumab has been recently approved for clinical use in children with XLH in Australia. This manuscript outlines a clinical practice guideline for the use of burosumab in children with XLH to assist local clinicians, encourage consistency of management across Australia and suggest future directions for management and research. This guideline also strongly advocates for all patients with XLH to have multidisciplinary team involvement to ensure optimal care outcomes and highlights the need to consider other aspects of care for XLH in the era of burosumab, including transition to adult care and the effective coordination of care between local health-care providers and specialist services. (© 2022 Paediatrics and Child Health Division (The Royal Australasian College of Physicians).)3: 17101.; Beck-Nielsen SS, Mughal Z, Haffner D et al. FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J. Rare Dis. 2019; 14: 58.; Che H, Roux C, Etcheto A et al. Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms. Eur. J. Endrocrinol 2016; 174: 325.; Linglart A, Biosse-Duplan M, Briot K et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr. Connect. 2014; 3: R13-30.; Haffner D, Emma F, Eastwood DM et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat. Rev. Nephrol. 2019; 15: 435-55.; Imel EA, DiMeglio LA, Hui SL, Carpenter TO, Econs MJ. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. J. Clin. Endocrinol. Metab. 2010; 95: 1846-50.; Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J. Clin. Endocrinol. Metab. 2006; 91: 3144-9.; Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician's guide to X-linked hypophosphatemia. J Bone Mineral Res. 2011; 26: 1381-8.; Ferizović N, Marshall J, Williams AE et al. Exploring the burden of X-linked hypophosphataemia: An opportunistic qualitative study of patient statements generated during a technology appraisal. Adv. Ther. 2020; 37: 770-84.; Imel EA, Glorieux FH, Whyte MP et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: A randomised, active-controlled, open-label, phase 3 trial. Lancet 2019; 393: 2416-27.; Schindeler A, Biggin A, Munns CF. Clinical evidence for the benefits of Burosumab therapy for X-linked hypophosphatemia (XLH) and other conditions in adults and children. Front Endocrinol. 2020; 11: 338.; Imel EA, Biggin A, Schindeler A, Munns CF. FGF23, hypophosphatemia, and emerging treatments. JBMR Plus. 2019; 3: e10190.; Portale AA, Carpenter TO, Brandi ML et al. Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: Results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period. Calcif. Tissue Int. 2019; 105: 271-84.; Insogna KL, Briot K, Imel EA et al. A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: Week 24 primary analysis. J. Bone Miner. Res. 2018; 33: 1383-93.; Whyte MP, Carpenter TO, Gottesman GS et al. Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. Lancet Diab. Endocrinol. 2019; 7: 189-99.; Carpenter TO, Whyte MP, Imel EA et al. Burosumab therapy in children with X-linked hypophosphatemia. N. Engl. J. Med. 2018; 378: 1987-98.; Sandy J, Cross R, Santos R, et al. Nine-month follow-up data on biochemical, clinical, radiological and functional parameters in a clinical cohort of children at Evelina London Children's Hospital with X-linked hypophosphataemia treated with Burosumab. Bone Abstracts. 2019.; Cheung M, Sakka S, Gilbey-Cross R, Harries M, Mathieson L. SUN-523 XLH outcome data from one centre experience with burosumab. Journal of the endocrine Society 2019; 3 (Supplement&#95;1). https://doi.org/10.1210/js.2019-SUN-523.; Swiglo BA, Murad MH, Schünemann HJ et al. A case for clarity, consistency, and helpfulness: State-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J. Clin. Endocrinol. Metab. 2008; 3: 666-73.; National Health and Medical Research Council. NHMRC levels of evidence and grades for recommendation. December 2009. Canberra, ACT. 2009.; Chesher D, Oddy M, Darbar U et al. Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations. J. Inherit. Metab. Dis. 2018; 41: 865-76.; Watts L, Wordsworth P. Chiari malformation, syringomyelia and bulbar palsy in X linked hypophosphataemia. BMJ Case Rep. 2015; 2015: bcr2015211961.; Hughes M, Macica C, Meriano C, Doyle M. Giving credence to the experience of X-linked hypophosphatemia in adulthood: An Interprofessional mixed-methods study. J. Patient Cent. Res. Rev. 2020; 7: 176-88.; Cheung M, Rylands AJ, Williams A, Bailey K, Bubbear J. Patient-reported complications, symptoms, and experiences of living with X-linked hypophosphatemia across the life-course. J. Endocr. Soc. 2021; 5: bvab070.; Lo SH, Lachmann R, Williams A, Piglowska N, Lloyd AJ. Exploring the burden of X-linked hypophosphatemia: A European multi-country qualitative study. Qual. Life Res. 2020; 29: 1883-93.; Theodore-Oklota C, Bonner N, Spencer H, Arbuckle R, Chen CY, Skrinar A. Qualitative research to explore the patient experience of X-linked hypophosphatemia and evaluate the suitability of the BPI-SF and WOMAC® as clinical trial end points. Value Health 2018; 21: 973-83.; Hawley S, Shaw NJ, Delmestri A et al. Higher prevalence of non-skeletal comorbidity related to X-linked hypophosphataemia: A UKparallel cohort study using CPRD. Rheumatology (Oxford) 2021; 60: 4055-62.; Valentijn PP, Schepman SM, Opheij W, Bruijnzeels MA. Understanding integrated care: A comprehensive conceptual framework based on the integrative functions of primary care. Int. J. Integr. Care 2013; 13: e010.; Bitar H, Alismail S. The role of eHealth, telehealth, and telemedicine for chronic disease patients during COVID-19 pandemic: A rapid systematic review. Digit. Health 2021; 7: 20552076211009396.; Andrews E, Berghofer K, Long J, Prescott A, Caboral-Stevens M. Satisfaction with the use of telehealth during COVID-19: An integrative review. Int. J. Nurs. Stud. Adv. 2020; 2: 100008.; Lim R, Shailam R, Hulett R et al. Validation of the radiographic global impression of change (RGI-C) score to assess healing of rickets in pediatric X-linked hypophosphatemia (XLH). Bone 2021; 148: 115964.; Thacher TD, Pettifor JM, Tebben PJ et al. Rickets severity predicts clinical outcomes in children with X-linked hypophosphatemia: Utility of the radiographic rickets severity score. Bone 2019; 122: 76-81.; Vega RA, Opalak C, Harshbarger RJ et al. Hypophosphatemic rickets and craniosynostosis: A multicenter case series. J. Neurosurg. Pediatr. 2016; 17: 694-700.; Boyce AM, Shawker TH, Hill SC et al. Ultrasound is superior to computed tomography for assessment of medullary nephrocalcinosis in hypoparathyroidism. J. Clin. Endocrinol. Metab. 2013; 98: 989-94.. Linking ISSN: 10344810. Subset: MEDLINE; Date of Electronic Publication: 2022 Apr 15. ; Original Imprints: Publication: Melbourne ; Boston : Blackwell Scientific Publications, c1990- <br />